Identification

Name
Methyclothiazide
Accession Number
DB00232  (APRD01104)
Type
Small Molecule
Groups
Approved
Description

A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)

Structure
Thumb
Synonyms
Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Duretic 5mgTablet5 mgOralAbbott1960-12-311999-08-09Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MethyclothiazideTablet5 mg/1OralMylan Pharmaceuticals1982-08-17Not applicableUs
International/Other Brands
Aquatensen / Duretic / Enduron
Categories
UNII
L3H46UAC61
CAS number
135-07-9
Weight
Average: 360.237
Monoisotopic: 358.956802649
Chemical Formula
C9H11Cl2N3O4S2
InChI Key
CESYKOGBSMNBPD-UHFFFAOYSA-N
InChI
InChI=1S/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16)
IUPAC Name
6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O

Pharmacology

Indication

For use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Also used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.

Structured Indications
Pharmacodynamics

Methyclothiazide, a diuretic-antihypertensive agent, is a member of the benzothiadiazine (thiazide) class of drugs. Methyclothiazide has a per mg natriuretic activity approximately 100 times that of the prototype thiazide, chlorothiazide. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic/natriuretic effects. Like other benzothiadiazines, methyclothiazide also has antihypertensive properties, and may be used for this purpose either alone or to enhance the antihypertensive action of other drugs.

Mechanism of action

Methyclothiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, methyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like methyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of methyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

TargetActionsOrganism
ASolute carrier family 12 member 1
inhibitor
Human
UCarbonic anhydrase 1
inhibitor
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 4
inhibitor
Human
Absorption

Rapidly absorbed following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Acute oral toxicity (LD50): >4000 mg/kg [Rat]. Symptoms of overdosage include electrolyte imbalance and signs of potassium deficiency such as confusion, dizziness, muscular weakness, and gastrointestinal disturbances.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Methyclothiazide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Methyclothiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Methyclothiazide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Methyclothiazide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Methyclothiazide.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Methyclothiazide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Aceclofenac.Approved
AcemetacinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Acemetacin.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methyclothiazide.Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Methyclothiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Methyclothiazide.Experimental
AlaproclateAlaproclate may increase the hyponatremic activities of Methyclothiazide.Experimental
AlclofenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Methyclothiazide.Approved
AlcuroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyclothiazide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Methyclothiazide.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methyclothiazide.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Methyclothiazide.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Methyclothiazide.Approved
AlminoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methyclothiazide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methyclothiazide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Methyclothiazide.Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Methyclothiazide.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Methyclothiazide.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Methyclothiazide.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Methyclothiazide.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amyl Nitrite.Approved
AndrographolideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Methyclothiazide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Methyclothiazide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Methyclothiazide.Investigational
AnisodamineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Methyclothiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Methyclothiazide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Apraclonidine.Approved
ApremilastThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Methyclothiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Methyclothiazide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Methyclothiazide.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Methyclothiazide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Methyclothiazide.Investigational
AtenololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Atenolol.Approved
AtracuriumThe serum concentration of Methyclothiazide can be increased when it is combined with Atracurium.Experimental
Atracurium besylateThe serum concentration of Methyclothiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Methyclothiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Methyclothiazide.Investigational
BalsalazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Methyclothiazide.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Methyclothiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Methyclothiazide.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Methyclothiazide.Investigational
BenactyzineThe serum concentration of Methyclothiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bendroflumethiazide.Approved
BenorilateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Methyclothiazide can be increased when it is combined with Benzatropine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Methyclothiazide.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Methyclothiazide.Approved
BevoniumThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Methyclothiazide.Experimental, Illicit, Withdrawn
BiperidenThe serum concentration of Methyclothiazide can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bisoprolol.Approved
BornaprineThe serum concentration of Methyclothiazide can be increased when it is combined with Bornaprine.Experimental
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Methyclothiazide.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Brimonidine.Approved
BromfenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methyclothiazide.Approved, Investigational
BucillamineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Methyclothiazide.Approved
BufexamacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bufexamac.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Methyclothiazide.Withdrawn
BumadizoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methyclothiazide.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methyclothiazide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methyclothiazide.Approved, Illicit, Vet Approved
CalcidiolMethyclothiazide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolMethyclothiazide may increase the hypercalcemic activities of Calcipotriol.Approved
CalciumMethyclothiazide may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateMethyclothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium CarbonateMethyclothiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Calcium CitrateMethyclothiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateMethyclothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateMethyclothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateMethyclothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateMethyclothiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Experimental, Vet Approved
Calcium lactate gluconateMethyclothiazide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium laevulateMethyclothiazide may decrease the excretion rate of Calcium laevulate which could result in a higher serum level.Experimental
Calcium pangamateMethyclothiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateMethyclothiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Candesartan.Approved
CandoxatrilMethyclothiazide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carbaspirin calcium.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Methyclothiazide.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Methyclothiazide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methyclothiazide.Illicit, Vet Approved
CarprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carvedilol.Approved, Investigational
CaseinMethyclothiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Methyclothiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methyclothiazide.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methyclothiazide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methyclothiazide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Methyclothiazide.Approved
CitalopramCitalopram may increase the hyponatremic activities of Methyclothiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Methyclothiazide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Methyclothiazide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Methyclothiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Methyclothiazide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Methyclothiazide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methyclothiazide.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clonidine.Approved
ClonixinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methyclothiazide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methyclothiazide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Methyclothiazide.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Methyclothiazide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Methyclothiazide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Methyclothiazide.Approved
CurcuminThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Curcumin.Investigational
CyclopentolateThe serum concentration of Methyclothiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cyclophosphamide.Approved, Investigational
CymarinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cymarin.Experimental
D-LimoneneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with D-Limonene.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Methyclothiazide.Investigational
DarifenacinThe serum concentration of Methyclothiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DelaprilMethyclothiazide may increase the hypotensive activities of Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Methyclothiazide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methyclothiazide.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Methyclothiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Methyclothiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Methyclothiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Methyclothiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Methyclothiazide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Methyclothiazide.Vet Approved
DexetimideThe serum concentration of Methyclothiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Methyclothiazide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methyclothiazide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methyclothiazide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methyclothiazide.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Methyclothiazide can be increased when it is combined with Dicyclomine.Approved
DifenpiramideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Methyclothiazide.Approved
DiflunisalThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Methyclothiazide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Methyclothiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methyclothiazide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methyclothiazide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methyclothiazide.Experimental, Illicit
DihydrotachysterolMethyclothiazide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methyclothiazide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Methyclothiazide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Methyclothiazide.Approved
DofetilideMethyclothiazide may increase the QTc-prolonging activities of Dofetilide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Doxazosin.Approved
DoxercalciferolMethyclothiazide may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Methyclothiazide.Investigational
DroxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methyclothiazide.Approved
DuloxetineMethyclothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with E-6201.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Methyclothiazide.Approved
EmeproniumThe serum concentration of Methyclothiazide can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Enalapril.Approved, Vet Approved
EnalaprilatMethyclothiazide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Methyclothiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Methyclothiazide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Methyclothiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Methyclothiazide.Approved
ErgocalciferolMethyclothiazide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Methyclothiazide.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Methyclothiazide.Approved
EstroneEstrone may increase the hypokalemic activities of Methyclothiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Methyclothiazide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.Approved
EtanautineThe serum concentration of Methyclothiazide can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
EthenzamideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Methyclothiazide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methyclothiazide.Approved, Illicit
EtodolacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Methyclothiazide.Approved
EtoricoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methyclothiazide.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Methyclothiazide can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
exisulindThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Methyclothiazide.Approved
FenoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Methyclothiazide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methyclothiazide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Methyclothiazide can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Methyclothiazide.Approved
FloctafenineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Methyclothiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Methyclothiazide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
FlunixinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Methyclothiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Methyclothiazide.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Methyclothiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Methyclothiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Methyclothiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Methyclothiazide.Approved
FlurbiprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluvoxamineFluvoxamine may increase the hyponatremic activities of Methyclothiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Methyclothiazide.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Furosemide.Approved, Vet Approved
GallamineThe serum concentration of Methyclothiazide can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Methyclothiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GitoformateThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Methyclothiazide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Methyclothiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methyclothiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methyclothiazide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methyclothiazide.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Methyclothiazide.Approved
GlycopyrroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Guacetisal.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Methyclothiazide.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methyclothiazide.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Methyclothiazide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methyclothiazide.Approved, Illicit
HexamethoniumThe serum concentration of Methyclothiazide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
HigenamineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Methyclothiazide can be increased when it is combined with Homatropine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methyclothiazide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Methyclothiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methyclothiazide.Approved, Illicit
HyoscyamineThe serum concentration of Methyclothiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Icatibant.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Methyclothiazide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Methyclothiazide.Investigational
Imidazole salicylateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Methyclothiazide.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Methyclothiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Methyclothiazide.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Indapamide.Approved
IndobufenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Methyclothiazide.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methyclothiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methyclothiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methyclothiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methyclothiazide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Methyclothiazide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methyclothiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methyclothiazide.Approved
Ipratropium bromideThe serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium bromide.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methyclothiazide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Methyclothiazide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methyclothiazide.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Methyclothiazide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isradipine.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Methyclothiazide.Investigational
IvabradineMethyclothiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Kebuzone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methyclothiazide.Approved
KetoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Methyclothiazide.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lanatoside C.Experimental
LeflunomideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Methyclothiazide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methyclothiazide.Approved
LevodopaMethyclothiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methyclothiazide.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Methyclothiazide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methyclothiazide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Methyclothiazide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Methyclothiazide.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Methyclothiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Methyclothiazide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Methyclothiazide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumMethyclothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Methyclothiazide.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Methyclothiazide.Approved, Investigational
LonazolacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Losartan.Approved
LoxoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Magnesium salicylate.Approved
MannitolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mannitol.Approved, Investigational
MasoprocolThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Masoprocol.Approved
MazaticolThe serum concentration of Methyclothiazide can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Methyclothiazide.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Methyclothiazide.Approved
Mefenamic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Methyclothiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Methyclothiazide.Experimental
MesalazineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methyclothiazide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methyclothiazide.Approved, Illicit
MethanthelineThe serum concentration of Methyclothiazide can be increased when it is combined with Methantheline.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metipranolol.Approved
MetixeneThe serum concentration of Methyclothiazide can be increased when it is combined with Metixene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metoprolol.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Methyclothiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Methyclothiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Methyclothiazide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Minoxidil.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mofebutazone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methyclothiazide.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Methyclothiazide.Approved
Mycophenolate mofetilThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Methyclothiazide.Approved, Investigational
NabumetoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methyclothiazide.Approved
NaproxenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Methyclothiazide.Investigational
NebivololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Methyclothiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nicardipine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Methyclothiazide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Methyclothiazide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Niflumic Acid.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Methyclothiazide.Approved
NimesulideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Methyclothiazide.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Methyclothiazide.Approved
NitroaspirinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitroprusside.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Methyclothiazide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Methyclothiazide.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Methyclothiazide.Approved
OleandrinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Oleandrin.Experimental
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Methyclothiazide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Olmesartan.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Methyclothiazide.Approved
OlopatadineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatMethyclothiazide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Methyclothiazide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Methyclothiazide.Approved
OrgoteinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Methyclothiazide can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Methyclothiazide can be increased when it is combined with Otilonium.Experimental
OuabainThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Methyclothiazide can be increased when it is combined with Oxitropium.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methyclothiazide.Approved
OxybutyninThe serum concentration of Methyclothiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methyclothiazide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methyclothiazide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Methyclothiazide can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyclothiazide.Approved, Vet Approved
PancuroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Methyclothiazide.Approved
ParecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Parecoxib.Approved
ParicalcitolMethyclothiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Methyclothiazide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Parthenolide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methyclothiazide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Vet Approved
PentoliniumThe serum concentration of Methyclothiazide can be increased when it is combined with Pentolinium.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methyclothiazide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Methyclothiazide.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methyclothiazide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Methyclothiazide.Approved, Withdrawn
PhenglutarimideThe serum concentration of Methyclothiazide can be increased when it is combined with Phenglutarimide.Experimental
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Methyclothiazide.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Methyclothiazide.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Methyclothiazide.Approved
PhenylbutazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methyclothiazide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methyclothiazide.Approved
PipecuroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Methyclothiazide.Approved
PirenzepineThe serum concentration of Methyclothiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Methyclothiazide.Investigational
PiroxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pirprofen.Experimental
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Methyclothiazide.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pranoprofen.Experimental
PrasteronePrasterone may increase the hypokalemic activities of Methyclothiazide.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Methyclothiazide.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Prazosin.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Methyclothiazide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Methyclothiazide.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Methyclothiazide.Approved
ProcyclidineThe serum concentration of Methyclothiazide can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Methyclothiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Methyclothiazide can be increased when it is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methyclothiazide.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propranolol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Proscillaridin.Experimental
PTC299The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Methyclothiazide can be increased when it is combined with Quinidine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Methyclothiazide.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methyclothiazide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methyclothiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
RescinnamineMethyclothiazide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methyclothiazide.Approved
ResveratrolThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Resveratrol.Experimental, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Methyclothiazide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Riociguat.Approved
RisperidoneMethyclothiazide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Methyclothiazide.Approved
RofecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Methyclothiazide.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methyclothiazide.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methyclothiazide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Methyclothiazide.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Methyclothiazide.Approved
SalbutamolSalbutamol may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Methyclothiazide.Approved
SalsalateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salsalate.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methyclothiazide.Approved
ScopolamineThe serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Methyclothiazide.Approved, Investigational, Vet Approved
SemapimodThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Methyclothiazide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methyclothiazide.Approved, Vet Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methyclothiazide.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Methyclothiazide.Approved
Sodium phosphateMethyclothiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Methyclothiazide can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Methyclothiazide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sotalol.Approved
SpiraprilMethyclothiazide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Spironolactone.Approved
SRT501The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Methyclothiazide.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methyclothiazide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methyclothiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Suxibuzone.Experimental
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Methyclothiazide.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Methyclothiazide.Approved
TarenflurbilThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Telmisartan.Approved, Investigational
TemocaprilMethyclothiazide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Methyclothiazide.Approved
TeriflunomideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methyclothiazide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Methyclothiazide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methyclothiazide.Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Methyclothiazide.Experimental
TimololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Timolol.Approved
TinoridineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Methyclothiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Methyclothiazide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tizanidine.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methyclothiazide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Methyclothiazide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methyclothiazide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methyclothiazide.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolmetin.Approved
TolterodineThe serum concentration of Methyclothiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateMethyclothiazide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Methyclothiazide.Approved
ToremifeneMethyclothiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methyclothiazide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Trandolapril.Approved
TranilastThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyclothiazide.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Methyclothiazide.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Methyclothiazide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Triamterene.Approved
TribenosideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tribenoside.Experimental
TrihexyphenidylThe serum concentration of Methyclothiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimethaphanThe serum concentration of Methyclothiazide can be increased when it is combined with Trimethaphan.Approved
TriptolideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Methyclothiazide.Withdrawn
TropatepineThe serum concentration of Methyclothiazide can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Methyclothiazide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Methyclothiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Methyclothiazide can be increased when it is combined with Tubocurarine.Approved
ValdecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Methyclothiazide.Approved, Investigational
VecuroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Methyclothiazide.Approved
VerapamilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Verapamil.Approved
VilanterolVilanterol may increase the hypokalemic activities of Methyclothiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methyclothiazide.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Methyclothiazide.Approved, Investigational
ZaltoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Methyclothiazide.Withdrawn
ZofenoprilMethyclothiazide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Human Metabolome Database
HMDB14377
KEGG Drug
D00656
KEGG Compound
C07765
PubChem Compound
4121
PubChem Substance
46509197
ChemSpider
3978
ChEBI
6847
ChEMBL
CHEMBL1577
Therapeutic Targets Database
DAP000746
PharmGKB
PA164748094
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
ATC Codes
C03AA08 — MethyclothiazideC03AB08 — Methyclothiazide and potassiumG01AE10 — Combinations of sulfonamides
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (74.8 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Abbott laboratories pharmaceutical products div
  • Ivax pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Usl pharma inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral5 mg
TabletOral5 mg/1
Prices
Unit descriptionCostUnit
Methyclothiazide powder11.32USD g
Enduron 5 mg tablet0.77USD tablet
Methyclothiazide 5 mg tablet0.77USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)225 °CPhysProp
water solubility11.2 mg/LNot Available
logP1.42HANSCH,C ET AL. (1995)
pKa9.4MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility0.824 mg/mLALOGPS
logP0.93ALOGPS
logP0.53ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)9.29ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.57 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity77.28 m3·mol-1ChemAxon
Polarizability31.65 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9834
Blood Brain Barrier-0.6866
Caco-2 permeable-0.6992
P-glycoprotein substrateSubstrate0.5317
P-glycoprotein inhibitor INon-inhibitor0.8518
P-glycoprotein inhibitor IINon-inhibitor0.8888
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.631
CYP450 2D6 substrateNon-substrate0.8261
CYP450 3A4 substrateNon-substrate0.532
CYP450 1A2 substrateNon-inhibitor0.6883
CYP450 2C9 inhibitorNon-inhibitor0.6493
CYP450 2D6 inhibitorNon-inhibitor0.858
CYP450 2C19 inhibitorNon-inhibitor0.808
CYP450 3A4 inhibitorInhibitor0.5094
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7345
Ames testNon AMES toxic0.8905
CarcinogenicityNon-carcinogens0.82
BiodegradationNot ready biodegradable0.9971
Rat acute toxicity1.9853 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9384
hERG inhibition (predictor II)Non-inhibitor0.9318
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-03di-9312000000-ae6f36f61e1e3b835a9f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00ri-0493000000-a1b477251688af0d67e8

Taxonomy

Description
This compound belongs to the class of chemical entities known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Organoheterocyclic compounds
Sub Class
Thiadiazines
Direct Parent
1,2,4-benzothiadiazine-1,1-dioxides
Alternative Parents
Secondary alkylarylamines / Organosulfonamides / Benzenoids / Aryl chlorides / Aminosulfonyl compounds / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
1,2,4-benzothiadiazine-1,1-dioxide / Secondary aliphatic/aromatic amine / Aryl chloride / Aryl halide / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Aminosulfonyl compound / Sulfonyl
show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzothiadiazine (CHEBI:6847 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Couloigner V, Loiseau A, Sterkers O, Amiel C, Ferrary E: Effect of locally applied drugs on the endolymphatic sac potential. Laryngoscope. 1998 Apr;108(4 Pt 1):592-8. [PubMed:9546276 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Meyerson LR, Nesta D: [3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells. Biochem Pharmacol. 1991 Mar 15-Apr 1;41(6-7):995-1000. [PubMed:1901209 ]
  2. Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8. [PubMed:2226620 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina an...
Gene Name
CA4
Uniprot ID
P22748
Uniprot Name
Carbonic anhydrase 4
Molecular Weight
35032.075 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:33